Neurocrine Biosciences Inc (NASDAQ:NBIX)
| 72.39 Delayed Data As of 4:00pm ET |  -3.12 / -4.13%Today’s Change | 71.88 Today|||52-Week Range 119.99 | -15.01% Year-to-Date |
Latest NBIX News | Press Releases
No recent news for Neurocrine Biosciences Inc.
Today’s Trading
| Previous close | 75.51 |
| Today’s open | 74.08 |
| Day’s range | 72.25 - 78.16 |
| Volume | 29,657 |
| Average volume (3 months) | 800,298 |
| Market cap | $7.1B |
Data as of 4:00pm ET, 01/27/2022
Growth & Valuation
| Earnings growth (last year) | +983.16% |
| Earnings growth (this year) | -55.21% |
| Earnings growth (next 5 years) | +9.90% |
| Revenue growth (last year) | +32.71% |
| P/E ratio | 15.9 |
| Price/Sales | 8.96 |
| Price/Book | 6.25 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NTLAIntellia Therapeutic... | -2.75 | -3.23% |
| ---- | ||
| NVAXNovavax Inc | -6.25 | -7.89% |
| ARWRArrowhead Pharmaceut... | -2.33 | -4.61% |
Data as of 4:45pm ET, 01/27/2022
Financials
| Next reporting date | February 11, 2022 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $1.0B |
| Annual profit (last year) | $407.3M |
| Net profit margin | 38.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
